Electrically pulsatile responsive drug delivery platform for treatment of Alzheimer’s disease
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Metal ions are involved in Aβ aggregate deposition and neurotoxicity via various processes, including acceleration of Aβ aggregation, disruption of normal metal homeostasis, and formation of reactive oxygen species (ROS). Although metal chelation is a promising therapeutic strategy for Alzheimer’s disease (AD), the widespread use of chelation therapy faces a significant problem; namely, it is difficult to differentiate toxic metals associated with Aβ plaques from those required by normal metal homeostasis. Furthermore, the multifactorial nature of AD and the current lack of an accepted unitary theory to account for AD neurodegeneration also restrict AD treatment through a single therapeutic strategy. This paper presents a novel bifunctional platform by integrating nonpharmacological and pharmacological cues into one system for AD treatment. This electrically responsive drug release platform, based on conducting polymer polypyrrole (PPy) incorporated with graphene-mesoporous silica nanohybrids (GSN) nanoreserviors, could realize on-demand controlled drug delivery with spatial and temporal control. Electrochemical stimulation can treat peripheral nerve injury (PNI) to stimulate neurite outgrowth. This novel system can also effectively inhibit Aβ aggregate formation, decrease cellular ROS, and protect cells from Aβ-related toxicity. The purpose of this research is to promote the design of noninvasive remote-controlled multifunctional systems for AD treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rapid induction of Alzheimer A beta amyloid formation by zinc
Bush, A., Pettingell, W., Multhaup, G., d Paradis, M., Vonsattel, J., Gusella, J., Beyreuther, K., Masters, C., & Tanzi, R. (1994) · Science · doi:10.1126/science.8073293 · Cited by 1,522 · cited 1×
“Although the molecular mechanisms of AD pathogenesis are not clearly understood owing to its complexity, recent advances have demonstrated that interactions between amyloid β peptide (Aβ) and transition metal ions are associated with the pathophysiology of AD [27-29].”
BackgroundCherny, R. A., Atwood, C. S., Xilinas, M. E., Gray, D. N., Jones, W. D., McLean, C. A., Barnham, K. J., Volitakis, I., Fraser, F. W., Kim, Y.-S., et al. (2001) · Neuron · doi:10.1016/s0896-6273(01)00317-8 · Cited by 1,447 · cited 1×
“The emergence of redox-active metals as key players in AD pathogenesis strongly argues that amyloid-specific metal-chelating agents and antioxidants be investigated as possible disease-modifying agents for treating this horrible disease [35-37].”
BackgroundIn vitro characterization of conditions for amyloid-β peptide oligomerization and fibrillogenesis
Stine, W. B., Dahlgren, K. N., Krafft, G. A., & LaDu, M. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210207200 · Cited by 1,015 · cited 1×
“AFM has proven well suited to the study of Aβ and other amyloidogenic proteins, because it generates detailed three-dimensional information at a nanometer scale [54, 57].”
BackgroundAtwood, C. S., Moir, R. D., Huang, X., Scarpa, R. C., Bacarra, N. M. E., Romano, D. M., Hartshorn, M. A., Tanzi, R. E., & Bush, A. I. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.21.12817 · Cited by 1,009 · cited 1×
“Although the molecular mechanisms of AD pathogenesis are not clearly understood owing to its complexity, recent advances have demonstrated that interactions between amyloid β peptide (Aβ) and transition metal ions are associated with the pathophysiology of AD [27-29].”
BackgroundRitchie, C. W., Bush, A. I., Mackinnon, A., Macfarlane, S., Mastwyk, M., MacGregor, L., Kiers, L., Cherny, R., Li, Q.-X., Tammer, A., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1685 · Cited by 988 · cited 1×
“The metal chelator, CQ has shown promising results in animal models and clinical trials, and new generation of metal ligand-based therapeutics are currently under development [56].”
BackgroundElectrically Controlled Drug Delivery from Biotin‐Doped Conductive Polypyrrole
George, P. M., LaVan, D. A., Burdick, J. A., Chen, C. ‐., Liang, E., & Langer, R. (2006) · Advanced Materials · doi:10.1002/adma.200501242 · Cited by 320
Choi, J.-S., Braymer, J. J., Nanga, R. P. R., Ramamoorthy, A., & Lim, M. H. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006091107 · Cited by 264
Hureau, C., & Faller, P. (2009) · Biochimie · doi:10.1016/j.biochi.2009.03.013 · Cited by 259 · cited 1×
“It has been suggested that the formation of ROS by Aβ-Cu2+ is another proposed mechanism of AD pathogenesis, which can cause oxidative stress and trigger a series of damage to cellular components such as DNA, lipids, and proteins [58].”
BackgroundPreliminary studies of a novel bifunctional metal chelator targeting Alzheimer's amyloidogenesis
Dedeoglu, A., Cormier, K., Payton, S., Tseitlin, K. A., Kremsky, J. N., Lai, L., Li, X., Moir, R. D., Tanzi, R. E., Bush, A. I., et al. (2004) · Experimental Gerontology · doi:10.1016/j.exger.2004.08.016 · Cited by 141 · cited 1×
“Most of the chelators possess limited ability to differentiate toxic metals associated with Aβ plaques from those associated with normal metal homeostasis [38].”
Background
Cited by
Croissant, J. G., Fatieiev, Y., Almalik, A., & Khashab, N. M. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201700831 · Cited by 594
Xu, G., Lu, Y., Cheng, C., Li, X., Xu, J., Liu, Z., Liu, J., Liu, G., Shi, Z., Chen, Z., et al. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202100852 · Cited by 336
Rahim, M. A., Jan, N., Khan, S., Shah, H., Madni, A., Khan, A., Jabar, A., Khan, S., Elhissi, A., Hussain, Z., et al. (2021) · Cancers · doi:10.3390/cancers13040670 · Cited by 323
Tau-Targeted Multifunctional Nanocomposite for Combinational Therapy of Alzheimer’s Disease
Chen, Q., Du, Y., Zhang, K., Liang, Z., Li, J., Yu, H., Ren, R., Feng, J., Jin, Z., Li, F., et al. (2018) · ACS Nano · doi:10.1021/acsnano.7b07625 · Cited by 280
“However, these nanotechnology based AD treatments are mainly focus on Aβ pathology, including the clearance of Aβ,(20-21) inhibition of Aβ aggregation and so on.(22-26) To the best of our knowledge, nanotechnology based smart strategy for tau-”
BackgroundChen, Y.-Y., Wang, M.-C., Wang, Y.-N., Hu, H.-H., Liu, Q.-Q., Liu, H.-J., & Zhao, Y.-Y. (2020) · Biomarker Research · doi:10.1186/s40364-020-00218-z · Cited by 33
“Fortunately, the emergence of a novel electrically controlled-release drug delivery platform that selectively retard metal-induced Aβ aggregation, could effectively inhibit Aβ aggregation, protect cells from Aβ-related cytotoxicity and decrease cellular ROS with no significant cytotoxic effects, which dramatically pro…”
Background
Metadata
- Authors
- Wu, L., Wang, J., Gao, N., Ren, J., Zhao, A., & Qu, X.
- Venue
- Nano Research
- Publisher
- Tsinghua University Press
- Published
- 2015-05-07
- Volume
- 8
- Issue
- 7
- Pages
- 2400-2414
- ISSN
- 1998-0000 (ISSN-L)
- 1998-0124
- OpenAlex
- W2162037667
- Cited by
- 43
- References
- 9
- FWCI
- 3.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Electrically pulsatile responsive drug delivery platform for treatment of Alzheimer’s disease. https://app.cochat.ai/papers/10.1007/s12274-015-0750-x
- The paper
- Wu, L., Wang, J., Gao, N., Ren, J., Zhao, A., & Qu, X. (2015). Electrically pulsatile responsive drug delivery platform for treatment of Alzheimer’s disease. Nano Research. https://doi.org/10.1007/s12274-015-0750-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.